Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) concerning whether a series of statements by Ironwood Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 26, 2016 Phase Five Research published an article on Ironwood Pharmaceuticals entitled "Uncovered: fatal issues linked with Ironwood's drug, Linzess."  According to the report, while Ironwood has stated that the side effects of Linzess are limited to the gastrointestinal tract, the drug's "side effects are not limited to the gastrointestinal (GI) tract," and that the drug is causing "previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes."

Following the news, NASDAQ: IRWD shares dropped 5.5% on April 26, 2016.

Based in Cambridge, Massachusetts, and founded in 1998 Ironwood Pharmaceuticals Inc engages in the research, development, and commercialization of human therapeutic products.

If you purchased shares of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) on or before April 26, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185